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Abstract
With the role of angiogenesis in tumor growth and progression firmly established, considerable
effort has been directed to antiangiogenic therapy as a new modality to treat human cancers.
Antiangiogenic agents have recently received much widespread attention but strategies for their
optimal use are still being developed. Gene therapy represents an attractive alternative to
recombinant protein administration for several reasons. This review evaluates the potential
advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene
transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively
suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages
and disadvantages of currently available gene transfer vectors and update novel developments in
this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an
effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.
Introduction
In 1971, Dr. Judah Folkman first proposed the hypothesis
that tumor growth is angiogenesis dependent [1]. Angio-
genesis, the growth of new capillary blood vessels from
preexisting vasculature, has long been appreciated for its
role in normal growth and development and now is
widely recognized for its role in tumor progression and
metastasis [2]. Angiogenesis is a multi-step process that
includes endothelial cell (EC) proliferation, migration,
basement membrane degradation, and new lumen organ-
ization. Within a given microenvironment, the angiogenic
response is determined by a net balance between pro- and
anti-angiogenic regulators released from activated ECs,
monocytes, smooth muscle cells and platelets.
The principal growth factors driving angiogenesis are vas-
cular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), and hepatocyte growth factor.
Other positive regulators are angiotropin, angiogenin,
epidermal growth factor, granulocyte colony-stimulating
factor, interleukin-1 (IL-1), IL-6, IL-8, platelet-derived
growth factor (PDGF), tumor necrosis factor-α (TNF-α),
and matrix proteins such as collagen and the integrins.
Several proteolytic enzymes critical to angiogenesis
include cathepsin, urokinase-type plasminogen activator,
gelatinases A/B, and stromelysin [3,4].
Tumor Growth and Metastasis are Angiogenesis 
Dependent
Transformed cells do not become tumorigenic unless they
acquire angiogenic potential [5]. The angiogenesis
response occurs early in tumor development and is rate
limiting for tumor progression [6]. A mutual stimulation
occurs between tumor and ECs by paracrine mechanisms.
Every increase in the tumor cell population must be pre-
ceded by an increase in new capillaries that converge upon
the tumor [4]. An angiogenic phenotype able to support
tumorigenicity can arise in a step-wise fashion in response
to both oncogene activation and tumor suppressor gene
loss and involve both a decrease in the secretion of
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inhibitors and the sequential upregulation of inducers of
angiogenesis [7]. This phenomenon is nearly universal;
most of the human solid tumors and hematopoietic
malignancies are angiogenesis dependent [8]. Addition-
ally, under the influence of endogenous angiogenesis
inhibitors, metastases remain dormant and tumor cell
proliferation is balanced by an equivalent rate of cell
death [9].
Angiogenesis as a Target for Cancer Therapy
With the role of angiogenesis in tumor growth and pro-
gression firmly established, considerable efforts have been
directed to antiangiogenic therapy as a new modality to
treat human cancers. A broad classification of angiogen-
esis inhibitors is illustrated in Figure 1. Currently available
antiangiogenic agents have recently received much wide-
spread attention – in fact, antiangiogenesis therapies for
cancer were honored as one of the ten runners – up for
Breakthrough of the Year in Science [10]. At the time of
this writing, there were over 60 angiogenesis inhibitors in
clinical trials and a number of these agents are listed in
Table 1[2].
These agents target ECs rather than the more conventional
target – the tumor cell itself. In addition, these agents
seem to preferentially target tumor endothelium versus
normal. Reasons may include that ECs proliferate more
rapidly in tumors than in normal tissues, activated tumor
ECs show higher expression of certain surface markers
than normal ECs, or that tumor vasculature is chaotic with
interrupted basement membrane [11,12]. Similar
differences are seen across most human tumors. Also
Antiangiogenic Inhibitors Figure 1
Antiangiogenic Inhibitors. The flowchart depicts the two major groups of antiangiogenic inhibitors, direct and indirect. It 
highlights the major differences between the groups and shows some representative examples in each category.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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advantageously, slowly growing, poorly vascularized as
well as rapidly growing highly vascularized tumors
respond to antiangiogenic therapy. Additional advantages
to antiangiogenic therapy include low toxicity, minimal
drug resistance, and repeated cycles of antiangiogenic
therapy may be followed by a prolonged tumor dormancy
without further therapy [13].
Antiangiogenic agents work through different mecha-
nisms, like inhibition of EC proliferation, migration, and
EC apoptosis. When an angiogenesis inhibitor induces EC
apoptosis in a microvessel, tumor cells supported by that
vessel subsequently undergo apoptosis. It has been estab-
lished that EC apoptosis precedes tumor cell apoptosis.
Various mechanisms might be responsible for EC-induced
tumor cell apoptosis. First, death of ECs limit the oxygen
and nutrient supply to the surrounding tumor cells. Sec-
ondly, growth factors produced by ECs are no longer
available for tumor cell growth [14]. Furthermore, even
without changes in microvessel density (MVD), apoptosis
of tumor cells occurs in proximity to endothelium follow-
ing treatment with angiogenesis inhibitors [15]. Endothe-
lial cell apoptosis also influences outcome of radiation
and chemotherapy. Garcia-Barros and co-workers have
shown that microvascular damage regulates tumor cell
response to radiation therapy [16]. Also, an antiang-
iogenic schedule of cyclophosphamide can control tumor
growth more effectively by sustained apoptosis of ECs
within the vascular bed of a tumor [17,18].
The more widely studied antiangiogenic agents include
naturally occurring angiogenesis inhibitors (angiostatin,
endostatin, thrombospondins, platelet factor-4, etc.);
inhibitors of EC growth (TNP-470, thalidomide, inter-
leukin-12 [IL-12] etc), inhibitors of proangiogenic mole-
cules (antibodies, antisense and soluble receptors for FGF,
VEGF); agents that interfere with basement membranes
and extracellular matrix (tissue inhibitors of matrix metal-
loproteinases [TIMPs]); antibodies to adhesion molecules
(αvβ3) and small inhibitors of receptor tyrosine kinases.
TNF-α, transforming growth factor-beta, and IL-4 are
bifunctional modulators. These molecules are either stim-
ulators or inhibitors depending on the amount, the site,
the microenvironment, and the presence of other
cytokines. Despite the enthusiasm and wide variety of
agents, results have been disappointing and strategies for
their optimal use are still being developed.
Table 1: Antiangiogenic Agents in Clinical trials
Drug Target Published Clinical Trials
Bevacizumab (Avastin) VEGF Phase I, II, III
VEGF-Trap VEGF Recruiting
NM-3 VEGF Recruiting
AE-941 (Neovastat) VEGF, MMP Phase I,II
IMC-1C11 VEGFR-2 Phase I
SU5416 VEGFR-2 Phase I, II
SU6668 VEGFR-2 Phase I
SU11248 VEGFR-1/2, PDGFR, KIT, FLT3 Phase I
PTK787/ZK222584 VEGFR-1/2 Phase I
ZD6474 VEGFR-2, EGFR Recruiting
CP-547,632 VEGFR-2, FGFR-2, PDGFR Recruiting
Endostatin Various Phase I
Angiostatin Various Phase I
TNP-470 Methionine aminopeptidase-2 Phase I
Thrombospondin-1 (ABT-510) CD36 Recruiting
Vitaxin Alphav/beta3 Phase I
EMD121974 (Cilengitide) Alphav/beta3, alphav/beta5 Phase I
Combretastatin A4 Endothelial tubulin Phase I
ZD6126 Endothelial tubulin Recruiting
2-methoxyestradiol (2-ME) microtubule Recruiting
DMXAA TNF-α induction Phase I
Thalidomide Various Phase I, II, III
BMS-275291 MMP Phase I
Celecoxib COX-2 Phase I, II, III
A composite list of various antiangiogenic agents in clinical trials and their targets is shown. VEGF: vascular endothelial growth factor; VEGFR: VEGF 
receptor; MMP: matrix metalloproteinases; PDGFR: platelet derived growth factor receptor; EGFR: epidermal growth factor receptor; FGFR: 
fibroblasts growth factor receptor.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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One obstacle in optimizing antiangiogenic strategies has
been the unavailability of good surrogate markers to fol-
low the success of antiangiogenic trials or to measure clin-
ical response. The most widely used angiogenic marker is
microvessel density (MVD). It has proven effective as a
prognostic indicator in several types of malignant tumors
including hematopoietic malignancies [19,20]. However,
the more recent thought is that MVD is not, by itself, an
indicator of therapeutic efficacy nor should it be used to
guide the stratification of patients for therapeutic trials
[21]. Recently, it has been shown that circulating mature
or bone marrow driven endothelial precursor cells play an
important role in neovascularization. The release of ang-
iogenic factors by tumor cells causes mobilization of bone
marrow derived ECs and hematopoietic cells which pro-
mote tumor growth. There is a close relation between an
increase in circulating ECs (CECs) and tumor progression,
and evaluation of CECs could be used as a clinically rele-
vant, non invasive angiogenesis marker [22].
New concepts such as vasculogenic mimicry and mosaic
tumor vessels have also been examined as a marker for
angiogenesis [23,24]. Vasculogenic mimicry was first
observed in melanoma and describes the ability of aggres-
sive melanoma cells to express endothelium-associated
genes and form extracellular matrix-rich vasculogenic-like
networks in three-dimentional culture [25,26]. They have
been observed in other malignancies as well. A strong
association between poor patient outcome and aggressive
tumors that contain vasculogenic networks have been
shown [27]. Individuals with melanomas that have
undergone vasculogenic mimicry have a poor prognosis
[25,28]. Endostatin, a widely studied antiangiogenic
agent, can inhibit endothelial cell-driven angiogenesis but
not vasculogenic mimicry [25].
Antiangiogenic Gene Therapy
Several lessons learned from early clinical trials in antian-
giogenic therapy would seem to support a role for antian-
giogenic gene transfer strategies in the future. These
lessons include:
(1) Genetic stability – Endothelial cells are much more
genetically stable than tumor cells and are therefore less
likely to accumulate mutations that confer early drug
resistance [29]. Gene therapy strategies that result in con-
stitutive expression of an antiangiogenic protein would be
expected to be more effective in this setting than a gene
therapy approach targeting a tumor cell that might
quickly develop an escape mechanism.
(2) Low, continuous dosing – Constitutive expression of
an antiangiogenic protein even at lower concentrations
than bolus doses may be more effective than the intermit-
tent peaks associated with repeated delivery of a recom-
binant protein. Some evidence for this thinking has been
demonstrated in a mouse model [30].
(3) Angiogenic switch – Understanding the genetic and
epigenetic events which transform a normal cell into a
cancer cell has been one of the major advances in the field
of tumor biology. However, in addition to these changes
that occur during transformation, the induction of tumor
vasculature, called the angiogenic switch, has increasingly
become recognized as a critical step in tumor propagation
and progression [31]. From this perspective, the body may
harbor many in situ tumors yet the tumors do not
progress to lethal tumors unless there is an imbalance
between a tumor's pro-angiogenic output and the body's
total angiogenic defense [32]. Gene therapy offers a strat-
egy whereby an individual could boost their endogenous
angiogenic defenses and tip the balance favorably.
(4) Cost of production – The production of functional
proteins can be expensive and the availability of some of
the recombinant proteins may become scarce. For exam-
ple, production of two of the most well known and widely
studied angiogenesis inhibitors – angiostatin and
endostatin – has recently halted [33]. Gene therapy offers
the opportunity for the patient to become his/her own
source of production, an endogenous factory for antiang-
iogenic protein production.
(5) Multiple pathways – The ability to inhibit multiple
angiogenic pathways could be made easier utilizing gene
transfer strategies which could achieve prolonged, sus-
tained levels of multiple therapeutic agents rather than
repeated, systemic boluses of numerous antiangiogenic
agents [34].
Candidate Genes for Antiangiogenic Gene 
Therapy
At this time, antiangiogenic gene therapy strategies
remain in the preclinical stage and have not yet been
tested in patients. We review several candidate genes
below:
Thrombospondin-1 (THBS1)
Thrombospondin-1 was the first naturally occurring ang-
iogenesis inhibitor to be identified and is a potent inhibi-
tor of angiogenesis [35]. Its activity as an antiangiogenic
antitumoral agent has been extensively demonstrated in
cell culture and mouse model systems and has been
reviewed extensively elsewhere [36]. The antiangiogenic
effects of THBS1 appear to be localized to a peptide
sequence containing the type I repeats domain, which
binds CD36 on ECs [37]. However, the utility of THBS1 as
a reproducible recombinant protein for clinical applica-
tion has been limited by its large size (450 kd), poor bio-
availability, and susceptibility to proteolytic breakdownJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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[37]. Currently, there are several Phase II studies which are
recruiting patients with advanced renal cell cancer,
advanced non-small cell lung cancer, refractory lym-
phoma and advanced sarcoma to evaluate the safety and
efficacy of a THBS1 mimetic called ABT-510.
Jin et al liposomally transfected THBS1 cDNA into
DU145, an human prostate cancer cell line [38]. There
was no significant inhibition of growth on the cell line in
vitro. However, the TSP-1 overexpressing construct inhib-
ited growth of DU-145 xenografts in Balb/c mice. More
recently, investigators constructed a recombinant adeno-
virus expressing a portion of the THBS1 gene which has
been shown to encode its antiangiogenic properties [39].
K562 human myelogenous leukemia cells were stably
transduced and demonstrated similar results. There was
little effect on in vitro growth but THBS1-transduced cell
growth in xenografts was dramatically inhibited.
Antiangiogenic Gene Therapy: Recent Developments Figure 2
Antiangiogenic Gene Therapy: Recent Developments. The figure depicts different modes of gene therapy directed to 
tumor endothelial cell (EC) and its microenvironment. The expression of EC specific cell surface molecules like, vascular 
endothelial growth factor receptor (VEGFR), E selectin or angiogenic growth factors (VEGF, FGF, PDGF) produced by tumor 
cells can be inhibited by specific antibodies or antisense RNA or using gene specific SiRNA. The targeted gene therapy can be 
achieved by using either viral vectors or nanoparticles carrying ligand (RGD) to endothelial cell surface specific receptors 
(αvβ5, αvβ3) to target antiangiogenic genes to tumor vasculature. The inhibitors can also selectively express in EC using 
endothelial cell specific promoters like endothelin 1 (EDT1). Ad: adenovirus; AAV: adeno-associated virus; Retro: retrovirus; 
VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; PDGF: platelet derived growth factor; TNF: tumor 
necrosis factor; RGD: Arginine-glycine-aspartic acid; SiRNA: small interfering RNAJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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Endostatin
First discovered in 1997, endostatin, a 20 kD internal frag-
ment of the alpha1 chain of type XVIII collagen, has
become the most well characterized of the body's angio-
genesis inhibitors [40]. Endostatin appears to inhibit ECs
via several pathways, including binding
alphaVbeta1integrin [41], inhibiting the receptor for
VEGF [42], and inhibiting cyclin D1 [43]. However, the
complete picture has yet to emerge. Endostatin was the
first endogenous inhibitor studied in clinical trials [44].
To date, endostatin has been evaluated in phase I clinical
trials only. Recombinant human endostatin appears to be
Table 2: Endogenous Inhibitors of Angiogenesis
Inhibitor Mechanism of action Refs
Thrombospondin-1 Platelet-derived 450 kD protein, binds CD 36 on ECs [37]
Cleavage products of ECM
Endostatin 20 kD C-terminal fragment of collagen XVIII, multiple pathways, incl. 
alpha5beta1 integrin
[171, 172]
Tumstatin Cleavage fragment of alpha3 chain of type IV collagen, activity mediated 
by alphavbeta3 integrin
[41]
Arresten 26-kDa NC1 domain of the alpha1 chain of type IV collagen, activity 
mediated by alpha1beta1 integrin
[53]
Canstatin 24 kD fragment of alpha2 chain of type IV collagen, activity via 
proapoptotic pathways in ECs
[54, 173]
Vastatin NC1 domain of type VIII collagen (alpha 1), induces cell cycle arrest and 
apoptosis
[55]
Restin 22 kD collagen XV fragment, inhibits EC migration, induces apoptosis [56, 174]
Plasma proteins
Angiostatin 38 kD internal fragment of plasminogen, binds ATP synthase, 
angiomotin, and alphavbeta3 integrin, multiple mechanisms of action
[60]
16-kd prolactin fragment 16 kD N-terminal fragment of prolactin, inhibits EC proliferation, 
induces apoptosis
[64, 65, 175]
Chemokines
Platelet factor-4 Chemokine with antiproliferative and antimigratory properties on ECs [176]
Interferon-inducible protein-10 (IP-10) Member of CXC chemokine family, potent immunomodulatory and 
antiangiogenic activity
[74]
Angiopoietins Bind EC-specific receptor Tie2, complex roles in angiogenesis [76]
Interleukins
IL-12 Heterodimeric pro-inflammatory cytokine, antiangiogenic effects via 
induction of IFN-gamma and IP-10
[78, 79]
IL-18 Cytokine with antiangiogenic activity via induction of IFN-gamma [86]
Interferons Multifunctional cytokines that regulate antiviral, antitumor, and cellular 
immune responses, potent antiangiogenic properties via inhibition of 
bFGF
[92]
Endothelial-monocyte activating polypeptide II (EMAP 
II)
Tumor-derived cytokine, induces tissue factor, upregulates TNF 
receptor 1, E-selectin and P-selectin on ECs, induces EC apoptosis
[94]
Tissue inhibitors of metalloproteinases (TIMPs) Block the activity of MMPs, complex role in tumor angiogenesis and 
tumor growth
[97]
Tumor necrosis factor alpha (TNF-alpha) 52 kD homotrimeric complex, potent vasculotoxic effects on tumors, 
activity mediated by TNF receptor
[99, 177]
p53 Tumor suppressor gene, wild-type antiangiogenic activity via increased 
thrombospondin-1 expression, decreased VEGF
[101, 102]
Serine protease inhibitors
Cleaved antithrombin III, maspin, pigment 
epithelium-derived factor (PEDF)
Potent antiangiogenic activities [178-180]
Vascular endothelial growth inhibitor (VEGI) Cytokine in the TNF superfamily expressed by ECs, promotes EC cell 
cycle arrest and apoptosis
[181, 182]
2-methoxyestradiol Endogenous metabolite of estrogen, exerts antiangiogenic effects by 
inhibiting HIF-1alpha
[183]
Tetrahydrocortisol Most potent naturally occurring angiostatic steroid [184]
Secreted protein acidic and rich in cysteine (SPARC)/
BM-40/osteonectin
34 kD matricellular protein, inhibits EC spread, abrogates binding of 
PDGF and VEGF to their receptors
[185, 186]
Domain 5 of high molecular weight kininogen (HMWK)/
kininostatin
Cleaved component of HMWK inhibits EC proliferation and induces 
apoptosis by binding EC tropomyosin
[187-189]Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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essentially free of significant dose-limiting toxicity but
also demonstrated no clinical responses in patients with
various solid tumors [45,46].
In our laboratory, we have evaluated endostatin in several
preclinical gene therapy models. Using a recombinant
adenovirus encoding murine endostatin, we were able to
achieve high circulating levels of endostatin in mice after
systemic delivery [47]. In this setting, there was marked
growth inhibition of MC38 murine colon carcinoma cells
implanted subcutaneously. We have also retrovirally
transduced a murine liver cell line NMuLi with murine
endostatin [48]. In vitro growth of these cells was not sig-
nificantly impacted but subcutaneously implanted
tumors were dramatically slowed and a survival advantage
was demonstrated in mice given intraperitoneal injections
of endostatin-producing clones versus controls.
Tumstatin
Tumstatin, a cleavage fragment of the alpha3 chain of type
IV collagen, represents an exciting potential target for gene
therapy. Human tumstatin prevents angiogenesis via inhi-
bition of EC proliferation and promotion of apoptosis; its
activity appears to be mediated by alpha v beta 3 integrin
[49]. Tumstatin also suppresses tumor growth in several
different mouse models [50-52]. At this time, gene trans-
fer experiments with tumstatin have not been published.
Arresten
Arresten, first identified in 2000, similarly represents a
potent angiogenic protein derived from the vascular base-
ment membrane [53]. This 26-kD NC1 domain of the
alpha1 chain of type IV collagen, functions as an anti-ang-
iogenic molecule by inhibiting EC proliferation, migra-
tion and tube formation. Its antiangiogenic activity
appears to be mediated by alpha1beta1 integrins on ECs.
Arresten inhibited the growth of two human xenograft
tumors in nude mice and the development of tumor
metastases in a murine model [53]. These results suggest
that arresten represents an excellent target for future gene
therapy experiments.
Canstatin
Canstatin, also identified in 2000, is an endogenous 24
kD fragment of the alpha2 chain of type IV collagen. It has
been demonstrated to inhibit EC migration and tube for-
mation and induce EC apoptosis selectively [54]. Cansta-
tin suppressed tumor growth in human xenograft mouse
models and demonstrated antivascular changes in these
tumors [54]. In our laboratory, we have cloned canstatin
into various gene transfer vectors and have achieved
promising results in some in vivo tumor models (unpub-
lished data).
Vastatin, Restin
Other basement membrane cleavage products include
vastatin, a fragment of the NC1 domain of collagen VIII.
Vastatin was shown to inhibit the proliferation of bovine
aortic ECs and induce cell apoptosis [55]. Restin, a 22 kD
fragment of human collagen XV, inhibits the migration of
ECs and suppresses the growth of tumors in a xenograft
renal carcinoma model [56].
Angiostatin
Angiostatin, a 38 kD internal fragment of plasminogen, is
one of the most potent endogenous inhibitors of
angiogenesis and has been shown to suppress tumor
growth and metastases in murine tumor models [57-59].
It appears to exhibit its antiangiogenic activity via interac-
tion with at least 3 potential receptors on the EC: ATP syn-
thase, angiomotin, and alphavbeta3 [60]. Angiostatin has
also been evaluated in Phase I clinical trials [61]. Again,
no significant dose-limiting toxicity was seen in patients
undergoing twice-daily subcutaneous injections and lev-
els were reached in which significant effects were seen in
preclinical models.
Investigators have studied angiostatin in a number of gene
transfer modalities. Recently, using a recombinant adeno-
associated virus (AAV) encoding kringles 1–3 of human
angiostatin, scientists were able to achieve continuous
and sustained expression of angiostatin in the sera of mice
for more than 6 months following a single injection of
recombinant vector [62]. AAV-mediated stable expression
of angiostatin slowed tumor growth and prolonged sur-
vival in the highly aggressive B16F10 melanoma and
Lewis lung carcinoma models of experimental metastasis.
Another interesting strategy that is increasingly being
studied is the combination of chemotherapeutics with
gene transfer. In the case of angiostatin, using the human
prostate cancer line PC3, tumor bearing mice were treated
with recombinant adenovirus encoding the kringle 1–3
region of angiostatin plus docetaxel versus adenovirus
alone and controls [63]. Tumor regression was seen only
in mice treated with the combination adenovirus chemo-
therapy strategy. This type of synergy may represent a
major antiangiogenic strategy in the future.
16 kD Prolactin Fragment
Another cleavage fragment of potential interest is the 16
kD prolactin fragment. Clapp et al first demonstrated its
antiangiogenic properties by demonstrating that it inhib-
its capillary EC proliferation, migration, and organization
into microvessels [64]. To date, the receptor mediating
human prolactin fragment activity remains unknown
[65].Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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The 16 kD prolactin fragment was expressed and secreted
from HCT116 human colon cancer cells stably transfected
with an expression vector encoding the 16 kD prolactin
fragement gene. Protein expression by the transfected
HCT116 cells inhibited tumor growth and neovasculari-
zation when implanted subcutaneously in Rag1 mice
[66]. In addition, using an adenovirus transfer vector, Kim
et al have shown that expression of the16 kD prolactin
fragment in prostate cancer cells markedly reduced their
ability to form tumors in a xenograft murine model
[66,67].
Platelet Factor-4
The chemokine platelet factor 4 (PF4), first identified as
an antiangiogenic agent in 1990 [68], has been shown to
suppress tumor growth in vivo in murine melanoma and
human colon carcinoma xenograft mouse models [69].
Both cell lines were not inhibited with PF4 administration
in vitro, suggesting a selective antiangiogenic antitumor
mechanism. In addition, Kolber et al demonstrated a
dose-dependent suppression of tumor metastases in an
experimental lung metastasis model [70]. Recombinant
PF4 was evaluated in a Phase I trial of patients with meta-
static colorectal cancer. PF4 was well tolerated in 11
patients though no clinical responses were noted [71].
Tanaka et al first reported effective antitumor activity of
PF4 using a gene transfer strategy [72]. Using retroviral
and adenoviral vectors to express a secretable form of
platelet factor 4, they demonstrated growth inhibition of
and hypovascularity in intracerebral gliomas in the PF4-
transduced group. Animal survival was also prolonged.
Additionally, Li et al retrovirally transduced KB cells, a
human head and neck squamous carcinoma cell line. PF4-
transduced cell growth was not inhibited in vitro but in
vivo, but subcutaneously implanted tumor growth was
inhibited. Anti-angiogenic changes were seen in xenograft
vascular histochemistry. These findings supported a selec-
tive antiangiogenic antitumor mechanism [73].
Interferon-inducible protein-10 (IP-10)
IP-10, a member of the C-X-C chemokine family, has a
multitude of biological functions, including potent
immunomodulatory and antiangiogenic effects [74]. In
our laboratory, we retrovirally transduced A375 human
melanoma cells with the human IP-10 gene and inocu-
lated nude mice subcutaneously. In vivo growth of IP-10-
transduced melanoma cells was markedly reduced com-
pared to controls and histologic analysis of these tumors
demonstrated reduced MVD [75].
Angiopoietins
The angiopoietins are a family of structurally related pro-
teins that specifically bind a common endothelial cell-
specific receptor tyrosine kinase, Tie2 [76]. The angiopoi-
etins play an essential and complex role in angiogenesis.
Angiopoietin-1 appears to activate Tie2, evidenced by
increased tyrosine phosphorylation of Tie2, whereas angi-
opoietin-2 seems to have both agonistic and antagonistic
properties depending on the local environment of the
Tie2 receptor [76]. The expression patterns of Ang-1 and
Ang-2 in the tumor and tumor vessel microenvironment
are complex and the precise role that each plays in tumor
angiogenesis is still being avidly studied and debated [76].
Recently, Stoeltzing et al liposomally transfected human
colon cancer cells with an Ang-1 construct. Cells were
then injected directly into the liver of nude mice. Tumor
burden and vessel counts were significantly lower in the
Ang-1-transduced cells as compared to controls. Another
approach targeting this complex pathway has been to
block Tie2 activation by the presence of a recombinant,
soluble Tie2 receptor. Lin et al constructed an adenoviral
vector encoding the recombinant, soluble Tie2 receptor
[77]. Administration of this vector to tumor bearing mice
– murine mammary carcinoma and murine melanoma –
significantly inhibited the growth rate of both tumors as
compared to controls. Administration of this vector also
slowed the development and progression of metastatic
disease in experimental metastases models.
Interleukin-12 (IL-12)
IL-12 is a heterodimeric pro-inflammatory cytokine
which has multiple functions, including the induction of
interferon-gamma, activation of T helper and NK cells,
and is a mediator between innate resistance and adaptive
immunity [78]. Pertinent to this review, IL-12 has been
identified as a potent antiangiogenic and antitumor agent
[79,80]. The exact mechanism is complex, including the
induction of secondary cytokines such as interferon-
gamma or chemokines such as interferon-inducible pro-
tein 10 – which may have direct cytotoxic effects and/or
antiangiogenic mechanisms for tumor inhibition [78].
Interleukin-12 has been evaluated as a cancer therapeutic
in Phase I trials. In Germany, recombinant human IL-12
was administered subcutaneously three times weekly to
patients with advanced renal cell carcinoma [81]. Dose
limiting toxicities included deterioration of performance
status, fever, vomiting, mental depression, leucopenia,
oral mucositis and elevation of hepatic enzymes. One
patient had a partial response and seven had stable dis-
ease. In 28 patients, one patient was seen to have a partial
response.
Additionally, recombinant human IL-12 (rhIL-12) was
administered as a twice-weekly intravenous infusion for 6
weeks in patients with metastatic renal cell cancer and
malignant melanoma [82]. Dose-limiting toxicities
included elevated hepatic transaminases and cytopenias.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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There was one partial response at the maximum tolerated
dose in a patient with renal cell cancer. At the MTD (n =
14), there was one partial response occurring after 6 cycles
of rhIL-12 in a patient with renal cell cancer and 2 patients
with renal cell cancer exhibited disease stabilization.
In a phase II study in the United States, rhIL-12 was
administered intravenously to 28 patients with advanced
ovarian cancer [83]. Again, there was one partial response.
Toxicities included grade 4 myelotoxicity and capillary
leak syndrome. Because of the toxicity of systemically
delivered IL-12, there is much enthusiasm for gene ther-
apy approaches which may allow achievement of high
concentrations in the local tumor environment but low
systemic levels. Several viral and nonviral vectors have
been developed to transfer IL-12 into tumor cells and/or
antigen presenting cells and have shown antitumor effects
[84]. For example, Caruso et al directly injected recom-
binant adenovirus expressing murine IL-12 intratumor-
ally in the MCA-26 tumor model [85]. Mice injected with
IL-12 expressing adenovirus achieved significant survival
advantage compared to controls.
Interleukin-18 (IL-18)
IL-18 has also been identified as an angiogenic inhibitor
and tumor suppressor [86]. Cao et al demonstrated its
antiangiogenic effects in a number of in vitro and in vivo
angiogenesis assays [86]. Systemic and intralesional
administrations of IL-18 produced significant suppression
of murine T241 fibrosarcoma growth in C57Bl6/J and
SCID mice. No inhibition of cell growth was seen in cul-
ture, suggestive of a specific antiangiogenic antitumor
mechanism.
Nagai et al transfected B16F10 melanoma cells with a
modified form of the IL-18 gene to enable tumor cells to
secrete IL-18 [87]. Significant growth inhibition was
observed in these modified melanoma cells as compared
to controls. Histologic analysis demonstrated reduced
vascularization. The antitumor effect appeared to be
mediated through induction of interferon-gamma.
IL-18 may also act synergistically with other inhibitors of
angiogenesis. Liu et al constructed two adenoviral vectors
encoding IP-10 and IL-18 [88]. Direct intratumoral injec-
tion of either vector alone into J558 murine myeloma
subcutaneous nodules delayed tumor growth to some
extent whereas coinjection of both vectors in the same
tumor nodule much more significantly delayed tumor
growth and even cured established tumors in 8 of 10 mice.
Interferons
The interferons (IFN) have been widely used for a number
of applications, including antiviral agents for hepatitis
and as cytotoxic agents for certain leukemias and some
bladder cancers [29]. They have also been shown to
inhibit angiogenesis and to induce tumor regression
through apparent antiangiogenic mechanisms [89,90].
One mechanism by which the IFN may exhibit this action
is by downregulation of pro-angiogenic factors secreted by
the tumor cell [91]. Inhibition of bFGF is the primary pro-
angiogenic factor that has been implicated [92].
Albini et al retrovirally transduced endothelial-like
Eahy926 cells with IFN-alpha1 and interferon-beta
murine cDNAs [93]. IFN-transduced cells demonstrated
decreased migration, invasion, and capillary-like structure
formation in matrigel. Additionally, co-inoculation of
Kaposi's sarcoma cell line and IFN-transduced cells
resulted in marked reduction of tumor growth in nude
mice as compared to controls alone.
Endothelial-monocyte activating polypeptide-II (EMAP-II)
EMAP-II is a tumor-derived cytokine with potent effects
on ECs, including induction of tissue factor, upregulation
of TNF receptor 1, and upregulation of E-selectin and P-
selectin [94]. EMAP-II inhibits EC proliferation but has lit-
tle effect on tumor cell or fibroblast proliferation [94].
Inhibition appears to be mediated through pro-apoptotic
pathways. Release of EMAP-II in melanoma cells appears
to render the tumor-associated vasculature sensitive to
TNF [95]. We used these findings to develop a gene trans-
fer strategy utilizing EMAPII to sensitize tumors to TNF-α
[96]. We constructed a recombinant vaccinia virus encod-
ing the human EMAP-II gene and transfected a human
melanoma cell line previously insensitive to TNF-α treat-
ment. EMAP-II expressing human melanoma cells
implanted in nude mice demonstrated significant tumor
regression after treatment with systemic TNF-α. Control
groups remained insensitive to TNF-α therapy.
Tissue Inhibitors of Metalloproteinases (TIMPs)
Matrix metalloproteinases (MMPs) play a critical role in
extracellular matrix remodeling, an essential component
of physiologic and pathologic angiogenesis and patho-
logic tumor growth and metastasis [97]. TIMPs function
to block the activity of MMPs and their role in tumor
growth and tumor angiogenesis is being actively studied.
The dominant paradigm has been that TIMPs serve an
important role in suppressing tumor invasion and metas-
tasis [97]. Numerous in vivo and in vitro studies have sup-
ported this assumption and have been extensively
reviewed [97]. For example, in a gene transfer strategy,
Wang et al, transfected full-length TIMP-4 cDNA into a
human breast cancer cell line. TIMP-4 transfected cells
demonstrated decreased invasiveness in an in vitro assay
and, in a nude mouse model, decreased growth and met-
astatic burden [98].Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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As the understanding of TIMPs evolves, however, it seems
that TIMPs play a much more complex role in tumor ang-
iogenesis and tumor growth and metastastic spread. In
fact, research has suggested that TIMPs, in certain scenar-
ios, may be proangiogenic and favor tumor growth [97].
This complexity may underpin some of the disappointing
results seen in clinical trials. Thus, a more thorough
understanding of TIMPs may be necessary before realizing
the potential of these agents as effective antitumor
therapies.
Tumor Necrosis Factor Alpha (TNF-α)
One of the most heralded cytokines of the last century has
been TNF-α. TNF is a homotrimeric complex of 52 kD
which is produced by many cell types and has been shown
to have profound antivascular and antitumor effects [99].
Unfortunately, phase I/II trials have been disappointing,
largely due to profound dose-limiting toxicity, most nota-
bly sepsis-like hypotension. The maximal tolerated dose
in clinical trials is about 1/50 of the effective dose in
murine tumor models [99]. Thus, TNF-α may represent an
ideal agent for localized gene transfer strategies, which
could allow for high locoregional doses but low systemic
levels.
One such effort has involved a replication deficient aden-
oviral vector called TNFerade. This vector expresses
human TNF-α and contains a radiation-inducible Egr-1
promoter. TNFerade was recently evaluated in a phase I,
dose escalation trial in patients with treatment refractory
solid tumors [100]. TNFerade was injected intratumorally
once weekly for 6 weeks with concomitant radiation.
TNFerade-related toxicities included fever, injection site
pain, and chills but dose-limiting toxicities were not seen.
Overall, 21 of 30 patients demonstrated an objective
response (5 CRs, 9 PRs) and, interestingly, in patients with
synchronous lesions, a more favorable tumor response
was seen in lesions treated with TNFerade + radiation as
compared to lesions treated with radiation alone (4 of 5
patients). Currently, Phase II randomized trials with
TNFerade are open for patients with rectal cancer and
unresectable pancreatic cancer. A single arm Phase II trial
is open for patients with locally advanced esophageal
cancer.
p53
Recently, attention has been focused on the role of the
p53 gene in angiogenesis. The p53 gene is an important
tumor suppressor gene and inactivated in over 50% of all
human cancers. Mutant p53 correlates with reduced
expression of thrombospondin-1, increased angiogenesis,
and malignant progression in melanoma [101]. Transfec-
tion of wild type p53 back into glioblastoma cells leads to
angiosuppression [102]. It has been shown that as non-
malignant fibroblasts progress to tumorigenicity, cells
become fully angiogenic in two steps. First, there is loss of
both alleles of wild-type p53, which causes a 20-fold drop
in secreted TSP and a fourfold increase in secreted VEGF
[7]. Second, angiogenic activity increases again on trans-
formation by activated ras oncogene due to a further two-
fold increase in secreted levels of angiogenic proteins.
Thus, there is a step-wise change in the angiogenic pheno-
type in response to oncogene activation and tumor sup-
pressor gene loss involving a decrease in the secretion of
inhibitors and the sequential up-regulation of inducers of
angiogenesis [7]. By inhibiting angiogenesis, p53
indirectly induces apoptosis and can revert tumors to a
dormant phenotype [103]. PTEN and phosphatidylinosi-
tol 3'-kinase inhibitors up-regulate p53 and block tumor-
induced angiogenesis in human brain ECs [104]. Thus,
restoration of p53 tumor suppressor gene may be an
important antiangiogenic treatment modality.
Gene Therapy Vectors
Clearly, the body of preclinical work in antiangiogenic
gene therapy demonstrates the potential to effectively
eradicate or control tumor burden in mouse models. The
major shortcoming for human application remains the
vectors used for gene transfer. A variety of nonviral vectors
– such as naked DNA, antisense RNA, small interfering
(Si) RNA, cationic liposomes – and viral vectors – includ-
ing adenoviruses, adeno-associated viruses, retroviruses,
lentiviruses, and bacteriophage vectors – have been used.
The following section summarizes the variety of nonviral
and viral vectors that have been utilized in gene therapy
and describes recent developments that may hold promise
for more effective therapies in the future.
Nonviral vectors
Naked Plasmid DNA
The simplest non-viral gene delivery system uses naked
expression vector DNA. Direct injection of free DNA into
certain tissues, particularly muscle, has been shown to
produce surprisingly high levels of gene expression, and
the simplicity of this approach has led to its adoption in a
number of clinical protocols. However, naked DNA and
peptides have a very short half life due to in vivo enzy-
matic degradation. Plasmid DNA suffers from low trans-
fection efficiency. However, there are reports showing
efficacy of naked plasmid DNA administration. Intra-
tumoral administration of naked plasmid DNA encoding
mouse endostatin inhibits renal carcinoma growth [105].
Intramuscular administration of the endostatin gene
could significantly retard the growth of metastatic brain
tumors [106]. A single intramuscular administration of
the endostatin gene could secret endostatin for up to 2
weeks and could inhibit systemic angiogenesis [107].
Injected endostatin gene also inhibited both the growth of
primary tumors and the development of metastatic
lesions. Thus, these results demonstrate the potential util-Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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ity of intramuscular delivery of an antiangiogenic gene for
treatment of disseminated cancers. However, in compari-
son to naked DNA, complexes of plasmid DNA with lipo-
somes are relatively more stable with higher potency for
transfection [108].
Cationic Liposomes
Liposomes are microscopic spherical vesicles of phos-
pholipids and cholesterol. Recently, liposomes have been
evaluated as delivery systems for drugs and have been
loaded with a great variety of molecules such as small drug
molecules, proteins, nucleotides and even plasmids. The
advantages of using liposomes as drug carriers are that
they can be injected intravenously and when they are
modified with lipids which render their surface more
hydrophilic, their circulation time in the bloodstream can
be increased significantly. They can be targeted to the
tumor cells by conjugating them to specific molecules like
antibodies, proteins, and small peptides [109]. The cati-
onic liposomes can significantly improve systemic deliv-
ery and gene expression of DNA [110]. Systemic,
liposome-mediated administration of angiostatin could
suppress the growth of melanoma tumors in mice [111].
Similar findings were observed by Chen and co-workers
with angiostatin and endostatin [112]. It has been shown
that angiogenic ECs take 15-33-fold more cationic lipo-
some:DNA complexes than corresponding normal ECs.
Thus, preferential uptake of cationic liposomes could be
used to target diagnostic or therapeutic agents selectively
to angiogenic blood vessels in tumors [113]. Liposomes
modified with angiogenic homing peptide for ECs can
strongly suppress tumor growth compared to unmodified
liposomes [114]. Janssen et al showed that the coupling of
cyclic RGD-peptides to the surface of PEG-liposomes can
target to tumor endothelium [115]. Tumor vessel-targeted
liposomes can also be used to efficiently deliver therapeu-
tic doses of chemotherapy [116].
Antisense RNA
Antisense oligodeoxynucleotides (ODNs) are synthetic
molecules that block mRNA translation. They can be used
as a tool to inhibit mRNA translation of a diseased gene.
There are reports demonstrating use of VEGF and VEGFR
antisense RNA in preclinical models. Angiogenesis and
tumorigenicity (as measured by MVD and tumor volume,
respectively) of human esophageal squamous cell carci-
noma can be effectively inhibited by VEGF165 antisense
RNA [117]. Im and co-workers used an adenovirus to
transfer antisense VEGF sequence into glioma cells in vitro
and in vivo [118]. The treatment resulted in reduction of
the level of the endogenous VEGF mRNA and protein and
inhibited growth of glioma tumors. VEGF mediated neo-
vascularization can also be inhibited by combination of
antisense oligonucleotides to VEGFR1 and VEGFR2 [119].
Expression of antisense RNA to Ang1 could reduce tumor
volume, decrease MVD and increase apoptosis in nude
mice [120]. Expression of antisense to integrin subunit
beta 3 inhibits microvascular EC capillary tube formation
in fibrin, with the extent of down-regulation correlating
with the extent of tube formation inhibition [121].
Small Interfering RNA (SiRNA)
The ability of small dsRNA to suppress the expression of a
gene corresponding to its own sequence is called RNA
interference (RNAi). The discovery of RNAi has added a
promising tool to the field of molecular biology.
Introducing the SiRNA corresponding to a particular gene
will knock out the cell's own expression of that gene. The
application of SiRNA to silence gene expression has pro-
found implications for the intervention of human dis-
eases including cancer. There are published reports using
SiRNA to silence expression of angiogenic genes. SiRNA
targeted to either subunit of the alpha6beta4 (a laminin
adhesion receptor) integrin reduced its cell surface expres-
sion and resulted in decreased invasion of MDA-MB-231
breast carcinoma cells [122]. Knockdown of Her-2/neu
expression by siRNA is associated with increased expres-
sion of the anti-angiogenic factor THBS-1 and decreased
expression of VEGF in human breast and ovarian cancer.
Thus, siRNA-mediated gene silencing may be a useful
therapeutic strategy for Her-2/neu-over-expressing breast
or ovarian cancer [123].
The disadvantage to simply introducing dsRNA fragments
into a cell is that gene expression is only temporarily
reduced. However, Brummelkamp et. al. developed a new
vector system, named pSUPER, which directs the synthesis
of siRNA in mammalian cells [124]. The authors have
shown that siRNA expression mediated by this vector
causes persistent and specific down-regulation of gene
expression, resulting in functional inactivation of the tar-
geted gene over longer periods of time. VEGF carries out
multifaceted functions in tumor development. DNA-vec-
tor based RNAi, in which RNAi sequences targeting VEGF
isoforms, has potential applications in isoform-specific
knock-down of VEGF [125].
However, the disadvantages of non viral vectors – stabil-
ity, non-specific uptake by various tissues, poor adsorp-
tion, short half life in the circulation, aggregate formation,
and low in-vivo potency for cell transfection – continue to
limit its use.
Viral Vectors
Delivery of genes expressing inhibitors of angiogenesis
using viral vectors represents a more effective strategy, as
it can produce stable and higher quantities of gene prod-
uct compared to the systemic infusion of antiangiogenic
DNA/protein. The main characteristics of any viral vector
are easy purification into high titers, to mediate targetedJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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gene delivery and prolonged gene expression with mini-
mal side effects. There are 5 main classes of clinically
applicable viral vectors; adenoviruses, adeno-associated
viruses (AAVs), retroviruses, lentiviruses, and herpes sim-
plex-1 viruses (HSV-1s) [126]. The main difference
between these vectors is retroviruses and lentiviruses can
integrate into the genome, whereas the other three classes
predominantly persist as extrachromosomal episomes.
Although the advantage of chromosomal integration is
long term transgene expression, these vectors can infect
dividing cells only. The non-integrated viral vectors can
infect non-dividing cells, but are not a favorable choice to
bring about stable genetic change.
Adenoviruses
Adenovirus is a double stranded DNA virus. It binds ini-
tially to the target cell through the viral fiber protein; how-
ever, the subsequent cell entry involves interaction
between the viral capsid penton proteins and integrins on
the target cell. Adenoviruses can be produced in high titers
and can efficiently deliver the therapeutic gene. Replica-
tion-defective adenoviral vectors are indeed particularly
well suited for cancer gene therapy as they lead to a tran-
sient, but robust, expression of the transgene, and efficient
in vivo gene transfer has been reported especially in the
liver after systemic injection. However, they do not inte-
grate into the host genome and the gene expression is
transient. Also, adenovirus elicits an immune response
resulting in an elimination of vector expressing cells.
Despite these apparent drawbacks, the adenovirus
remains a popular vector for gene therapy due to its high
gene transfer efficiency and high level of expression in a
wide variety of cell types. Adenovirus can be targeted to
pulmonary endothelium by complexing it with a bispe-
cific antibody to viral particle and angiotensin-converting
enzyme [127]. Bilamellar cationic liposomes can also be
used to encapsulate adenovirus. The encapsulated adeno-
virus can transduce CAR negative cells and is resistant to
the neutralizing anti-adenoviral antibodies, allowing the
readministration of the adenovirus [128].
Retroviral Vectors
Retroviruses are a class of enveloped viruses containing a
single stranded RNA molecule as the genome. Retrovirus
vectors have been used in the majority of human gene
transfers. They are able to efficiently integrate perma-
nently into the human genome where they provide the
basis for permanent expression of up to 8–9 kb of foreign
DNA. Simple retroviruses, such as murine leukemia virus
(MLV), and the vectors derived from them, require cell
division for infection and thus possess a degree of inher-
ent specificity for the rapidly dividing cells of neoplastic
tissue [129]. Though transgene expression is usually ade-
quate in vitro, prolonged expression is difficult to attain in
vivo. Also, retroviruses are inactivated by complement
proteins and inflammatory IFN, specifically IFN-alpha
and IFN-gamma [130,131]. A major shortcoming of retro-
virus-derived vectors is their tendency to revert to replica-
tion-competent retrovirus (RCR), which could lead to
fatal neoplasms. With the use of the latest packaging cell
lines and vectors, the risk of RCR-generation has been
drastically reduced. Currently, the greatest safety concern
of using retroviral vectors is related to the risk of malig-
nant transformation following oncogene activation due
to random retroviral genomic integration and will be dis-
cussed in more detail below.
Adeno-associated virus (AAV)
The adeno-associated virus (AAV) is a vector that com-
bines some of the advantages of both the adenoviral and
retroviral vectors. It can efficiently transfer genes to a
number of different cell types. The broad host range, low
level of immune response, and longevity of gene expres-
sion observed with these vectors has enabled the initia-
tion of a number of clinical trials using this gene delivery
system [132]. A potential barrier, however, is the low
transduction efficiencies of recombinant AAV vectors.
AAV tropism can be genetically engineered by use of
phage display-derived peptides to generate vectors that are
selective for the vasculature [133]. The journal Nature
recently reported concerns that there is a possibility that
recombinant AAV vectors may cause or contribute to can-
cer in gene therapy subjects [134]. However, because of
infrequent integration efficiency of AAV, the risk of cancer
in current AAV trials is negligible [135].
Lentiviral Vectors
Lentiviral vectors represent a new vector system that can
achieve permanent integration of the gene into non-divid-
ing cells. Gene transfer can be achieved in very quiescent
cells, nondividing or terminally differentiated cells such
as neurons. Lentiviral vectors are especially useful in trans-
ducing cells which lack receptors for adenoviruses. A
broad tissue tropism for lentivirus can be achieved using
variety of viral envelopes [136]. So far, lentiviral vectors
expressing matrix metalloproteinase-2 (MMP-2), angi-
ostatin and endostatin have been developed [136,137].
However, lentivirus has a low transduction efficiency for
ECs and may result in significant vector-associated cyto-
toxicity [136].
Herpes Simplex Virus
The herpes simplex virus (HSV) thymidine kinase gene
(tk) therapy with ganciclovir forms the basis of a widely
used strategy for suicide gene therapy [138]. HSV can also
be used to deliver a therapeutic gene of interest, especially
to the nervous system. The advantages in using HSV
include its wide host range, its ability to accommodate
large genes, and its ability to establish long-lived asymp-
tomatic infections in neuronal cells. However, the virus'sJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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ability to replicate lytically in the brain, under some cir-
cumstances causing encephalitis, has led to fears about its
potential safety for ultimate use in humans.
Targeted Gene Therapy
The systemic delivery of viral vectors can lead to non spe-
cific uptake by various different tissues and hence result
into systemic toxicity because of transgene expression.
Local delivery can circumvent this problem; however,
many times the tumor is not accessible for local injection.
Hence, transgene expression in the targeted tissue is very
important. Targeting tumor vasculature by gene therapy
represents an ideal target, as tumor blood vessels are easily
accessible to systemically applied vectors. Certain consid-
erations such as vascular dependency of a tumor, the dif-
ferences between tumor associated and normal
vasculature, and accessibility of tumor vasculature to cir-
culating vectors must be addressed.
Targeted viral vectors can be constructed in several ways.
The first approach is pseudotyping, in which one species
of virus is made to incorporate the envelope protein of
another virus. Adeno-associated virus genome with its
inverted terminal repeats can be packaged in the capsids
of different serotypes which enables transduction with
broad specificity [139]. The second approach is to geneti-
cally modify the viral capsid protein to incorporate a
small peptide coding for a specific receptor and hence,
allow targeting by ligand-receptor internalization. Tissue
specific targeting can also be achieved by conjugating spe-
cific antibodies to receptors onto the viral capsids [140].
Various transductional and transcriptional approaches
have also been devised to improve targeting of adenoviral
vectors. Using this approach, Reynolds et al increased the
selectivity of transgene expression by 300,000 for lung
versus liver, the usual site of vector sequestration [141].
Another strategy is to use vectors guided by EC specific
promoters, such as the promoters for endoglin, endothe-
lin-1 gene, and von Willebrand factor. The murine pre-
proendothelin-1 promoter is highly specific for ECs and
could be use to achieve very high levels of gene expression
in vascularized tumor metastases compared to normal or
less vascularized primary tumor [142].
Whereas most antiangiogenic agents prevent new blood
vessel formation, vascular targeting agents (VTAs) destroy
pre-existing blood vessels of solid tumors. VTAs can be
more active in large tumors and produce a characteristic
pattern of widespread central necrosis. Combination of
VTAs and angiogenic inhibitors can lead to synergistic
effects. Two major types of VTAs are ligand-directed VTAs
to deliver gene product to tumor endothelium and small
molecule VTAs that exploit pathophysiological differences
between tumor and normal endothelium [143]. The lig-
and-directed VTAs use ligands specifically expressed on
the tumor endothelium, eg. VEGF receptors, αvβ3
integrins, tissue factor, and cell adhesion molecules like
VCAM-1. A small molecule VTA described thus far is the
tubulin binding agent combretastatin, which destabilizes
the tubulin cytoskeleton. It has antiproliferative and cyto-
toxic effects on both proliferating tumor and ECs. It
results in extensive and prolonged shut-down of blood
flow in established tumor blood vessels, with much less
effect in normal tissues [144]. Recently, bacteriophage
vectors have been developed for targeted gene delivery of
antiangiogenic VTAs.
Phage Vectors
Phage display represents a novel method of individually
displaying up to tens of billions of peptides, proteins,
including human antibodies and enzymes, on the surface
of a small bacterial virus called a phage. Phage display
allows producing and searching through large libraries of
peptides and proteins to rapidly identify those com-
pounds that bind with high affinity and high specificity to
targets of interest. Pasqualini and Ruoslahti first distin-
guished active proliferating microvascular ECs and quies-
cent nonproliferating ECs using an in vivo phage display
technique [145]. The phage display peptide libraries have
been used to identify peptides that home to tumors
through the circulation and that specifically bind to the
tumor ECs or lymphatic cells [146,147]. Phage displaying
an Arg-Gly-Asp (RGD)-containing peptide binds to alpha
v integrins with high affinity and homes to tumors when
injected intravenously into tumor-bearing mice. Phage
displaying the cyclic peptide His-Try-Gly-Phe (HWGF)
specifically targets angiogenic blood vessels in vivo and
specifically inhibits MMP-2 and MMP-9 metalloprotein-
ases [148]. MMP-2 can directly bind to αvβ3 integrin on
tumor cells [149]. These tumor endothelial specific signa-
tures were later described by Dr. Folkman as an ang-
iogenic zip codes [150].
The picture of integrins and their ligands is very complex.
The αvβ3 integrin is expressed on proliferating ECs such
as those present in growing tumors of various origins.
VEGF-induced EC migration requires interaction between
VEGF receptor2 (VEGFR2) and αvβ3 to drive the activa-
tion of downstream mitogenic pathways [151]. Several
studies have demonstrated that αvβ3 is involved in
melanoma cell invasion and promotes metastasis
(reviewed in [152]). Although the precise mechanisms of
αvβ3-promoted tumor progression are not clear, various
studies suggest roles for αvβ3 in selective tumor cell
migration, generation of growth and survival signals,
intracellular signaling and generation of MMPs [152]. It
has been observed that antibody to αvβ3 integrin can
block angiogenesis without affecting the normal vascula-
ture [115,153]. The αvβ3 integrin can also be blockedJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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with small peptides containing Arg-Gly-Asp (RGD) amino
acid sequence. Exposure of human EC to TNF and inter-
feron-γ decreases αvβ3-dependent EC adhesion and sur-
vival [154].
Other integrins such as αvβ5, and αvβ1 are also consid-
ered very significant for the regulation of angiogenesis.
The β3 chain play a significant role in promoting angio-
genesis, although the lack of it can also promote angio-
genesis, given that the angiogenesis inhibitor tumstatin
binds through this receptor [41]. Also, the expression of
integrin αvβ6, a fibronectin receptor, promotes migration
and invasion in squamous carcinoma cells [155].
Bacteriophages expressing ligands for specific receptors
like integrins, growth factors, and antibody can be made
to infect mammalian cells [156-158]. The phage vectors
are an attractive alternative to existing animal viral vectors
because they lack intrinsic tropism for mammalian cells
and can be produced in bacteria in large titers. Currently,
phage vector transduction efficiency (1–4%) is considera-
bly lower than most viral vectors. Burg et al tested 14
human cancer cell lines from different tissues, showing
viral transduction efficiency varies from 0.001 to 10%.
However the transduction efficiency can be improved sub-
stancially by treating cells with camptothecin [159]. Thus,
using specific targets in the tumor endothelium, it is pos-
sible to target gene therapy specifically to the tumor
endothelium.
Nanoparticles
In recent years, significant effort has been devoted to
developing nanotechnology for drug delivery since it
offers a suitable means of delivering small molecular
weight drugs as well as macromolecules such as proteins,
peptides or genes [160]. These systems in general can be
used to provide targeted (cellular/tissue) delivery of drugs,
to improve oral bioavailability, to sustain drug/gene effect
in target tissue, to solubilize drugs for intravascular deliv-
ery, and to improve the stability of therapeutic agents
against enzymatic degradation (nucleases and proteases),
especially of protein, peptide, and nucleic acids drugs
[161]. Nanoparticles (NPs) are submicron-sized poly-
meric colloidal particles with a therapeutic agent of inter-
est encapsulated within their polymeric matrix or
adsorbed or conjugated onto the surface [162]. NPs have
in general relatively higher intracellular uptake because of
their smaller size. The therapeutic efficacy of the NPs
could be due to their ability to protect the therapeutic
agent from degradation due to lysosomal enzymes and
sustained intracellular retention. Nanoparticles conju-
gated to the contrast agent like gadolinium can be used in
magnetic resonance based imaging techniques [163,164].
They can be targeted to tumor endothelium by covalently
coupling to different ligands or antibodies [165]. David
Cheresh's group at the Scripps Research Institute showed
that NPs coupled to an integrin αvβ3-targeting ligand can
deliver genes selectively to angiogenic blood vessels in
tumor-bearing mice with no detectable levels in the other
tissues [165]. Further, the authors showed that NPs conju-
gated to a mutant Raf gene blocks endothelial signaling
and angiogenesis in response to multiple growth factors.
Current State of Gene Therapy Clinical Trials
Despite the tantalizing promise of gene therapy, there has
been much recent alarm in the field and no review of the
current state of and potential future role of gene therapy
would be complete without noting the major current con-
troversy in the field. The first true successes of gene
therapy in clinical trials were reported in 2000 and 2002,
in which scientists successfully treated children suffering
from SCIDs by retrovirally transducing hematopoietic
stem cells with the gamma-c gene [32]. Unfortunately, 2
of the 10 children subsequently developed leukemia-like
conditions, eventually attributed to retroviral vector inte-
gration in proximity to the LMO2 proto-oncogene pro-
moter, leading to aberrant transcription and expression of
LMO2 [166]. These cases garnered enormous attention
from scientists, regulators and the general public [167].
Reaction varied but some countries even imposed a
general moratorium on trials involving retroviral gene
transfer. Though in most countries trials have now been
allowed to resume, the reaction has thrown the field of
gene therapy into recession and has discouraged many sci-
entists from starting new clinical trials [167].
Future Directions
As addressed above, the development of better vectors
remains the cornerstone for advancing the field of antian-
giogenic gene therapy of cancer. Important concerns
about oncogene activation by retroviral integrating vector
systems remain. Also, currently available nonviral vectors
are not very efficient.
Future areas of investigation also include:
Combination Therapy
Studies have shown advantages to combining antiang-
iogenic agents with each other, as well as with chemother-
apy and radiation [168]. Combining agents that target a
number of different and synergistic pathways may yield
improved antitumor effects and long term suppression of
metastatic progression. For example, the combination of
SU5416, VEGFR2 tyrosine kinase inhibitor and low-dose
endostatin reduced tumor growth more efficiently than
monotherapy alone [169]. Whereas SU5416 specifically
inhibits vascular endothelial growth factor signaling, low-
dose endostatin is able to inhibit a broader spectrum of
diverse angiogenic pathways directly in the endothelium.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/22
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Gene therapy strategies certainly need to be further evalu-
ated in these combination settings.
Preventive Therapy
More specific to the field of antiangiogenic gene therapy,
there is much enthusiasm for the role that antiangiogenic
agents may play in preventive therapy. Because antiang-
iogenic therapy is generally less toxic and less susceptible
to acquired resistance, angiogenesis inhibitors have been
considered an ideal prophylactic agent in patients at high
risk for cancer or for recurrence of cancer [29]. At our insti-
tution, we are currently recruiting patients with previously
resected recurrent or metastatic colorectal cancer and ran-
domizing these patients to receive thalidomide or pla-
cebo. Gene therapy offers an ideal strategy for long term,
continuous production of antiangiogenic agents that may
prevent development of primary or recurrent disease.
Chronic Disease Treatment
Additionally, many leaders in the field of angiogenesis
now believe that some of the most important future can-
cer therapies may not completely eradicate all tumor cells
in an individual but, instead, may turn cancer into a
chronic manageable disease [32]. Gene therapy strategies
leading to increased production of endogenous angiogen-
esis inhibitors would seem perfectly suited to support
such an approach by tipping the balance toward a more
antiangiogenic state.
Conclusions
Enthusiasm for antiangiogenic approaches to cancer ther-
apy has never been higher, given the recent approval by
the FDA for the first angiogenesis inhibitor and given the
recent encouraging clinical trial data [170]. The versatility
shown by the field of antiangiogenesis has enabled many
human cancers to be realistically considered for therapeu-
tic intervention and has considerably broadened the
scope of gene therapy. Because of the difficulties and high
costs of manufacturing numerous endogenous inhibitors
of angiogenesis and because of the need for chronic
administration of these agents, gene therapy remains an
exciting strategy to circumvent these difficulties. Although
no clinical gene therapy trials to date have utilized a
focused antiangiogenic strategy, an abundance of preclin-
ical research demonstrates that gene therapy-based
antiangiogenesis approaches are an effective means of
controlling and even eradicating tumor growth in animal
models. As better vectors are developed, combination
strategies continue to evolve, and increased understand-
ing of the complex role that endogenous angiogenesis
inhibitors play in tumor growth and progression takes
place, antiangiogenic gene therapy will certainly be evalu-
ated in future clinical trials.
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